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Abstract In cultured endothelial cells, incubation with TNF-oc 
(50 ng/ml) for 48 h markedly reduced viability of endothelial 
cells. A 6 h preincubation with Sper/NO ( 0 . 0 3 - 1 U.M) protected 
endothelial cells in a concentration-dependent manner and 
increased viability by 63% of control. The NO scavenger PTIO 
(30 uM) completely abolished cytoprotection by Sper/NO. A 
cytoprotective effect comparable to Sper/NO was observed when 
preincubating the cells with 8-bromo cyclic GMP (1-10 \iM). 
Moreover, no protection by Sper/NO occurred in the presence of 
ODQ (0.1 jiM), a selective inhibitor of soluble guanylyl cyclase. 
Our results demonstrate that N O produces a long-term 
endothelial protection against cellular injury by TNF-a , 
presumably via a cyclic GMP-dependent pathway. 
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1. Introduction 
Nitric oxide (NO) is known as a cytotoxic effector molecule 
produced by the immune surveillance system [1]. Also, under 
conditions of ischemia, N O has been implicated as a mediator 
of tissue injury, e.g. during neuronal destruction in vascular 
stroke [2]. However, recent studies suggest that N O at lower 
non-toxic levels may also function as a cytoprotective and 
antioxidant agent in different models of oxidative stress. 
Thus, Wink and co-workers [3] reported N O to prevent cel-
lular damage induced by hydrogen peroxide in lung fibro-
blasts. Similar results were published by Motterlini et al. [4] 
who found that pretreatment with N O donors rendered the 
vascular endothelium more resistant against the toxic effects 
of oxygen-free radicals, i.e. exogenously applied hydrogen per-
oxide. Possible NO-dependent cytoprotective mechanisms in-
clude direct neutralization of Superoxide radicals [5] or acti-
vation of an antioxidant defense system such as heme 
oxygenase or ferritin [4,6,7]. 
Whereas the studies mentioned above demonstrate protec-
tive effects of N O against exogenous sources of oxygen radi-
cals, little is known about the ability of N O to antagonize 
cytotoxicity induced by endogenous formation of oxygen rad-
icals, e.g. in response to receptor-dependent agonists. Tumor 
necrosis factor-a ( T N F - a ) is a proinflammatory cytokine and 
mediator of septic shock with a direct toxic effect on the 
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endothelium resulting in endothelial lesions which may favor 
thrombus formation, atherogenesis and vasodilation via in-
duction of N O synthesis in the underlying smooth muscle cells 
[8,9]. This direct cytotoxicity of T N F - a has been attributed, at 
least in part, to the formation of reactive oxygen species [10-
12]. Based on these observations and using the N O releasing 
agent spermine N O N O a t e (Sper/NO), the present study ad-
dresses whether N O is capable of reducing cytotoxicity by 
T N F - a in endothelial cells. 
2. Materials and methods 
2.1. Materials 
Bovine pulmonary artery endothelial cells (ATCC CCL 209) were 
obtained from the American Type Culture Collection, Rockville, MD, 
USA. Fetal bovine serum, Dulbecco's modified Eagle medium and 
penicillin-streptomycin were obtained from Gibco, Eggenstein, Ger-
many. TNF-a was a gift of Knoll AG, Ludwigshafen, Germany. Sper/ 
NO, lH-[l,2,4]oxadiazole[4,3-a]quinoxalin-l-one (ODQ) and 2-Phe-
nyl-4,4,5,5,-tetramethylimidazoline-l-oxyl-3-oxide (PTIO) were from 
Alexis Deutschland, Grünberg, Germany. Crystal violet and all other 
chemicals were bought from Sigma, Deisenhofen, Germany. 
2.2. Cell culture 
Endothelial cells were maintained and subcultured in Dulbecco's 
modified Eagle medium supplemented with 15% fetal bovine serum, 
100 U/ml penicillin and 100 (ig/ml streptomycin [11]. The cells were 
grown in a humidified incubator at 37°C and 5% CÖ2. 
2.3. Incubation procedure 
Endothelial cells were seeded at 2X 104 cells/well in 96 well micro-
titer plates in 100 ul of media containing 15% fetal bovine serum. 
After a 48 h incubation cells reached confluence and Sper/NO or 8-
bromo cyclic GMP was added. PTIO and ODQ were added 10 min 
prior to Sper/NO. After an additional 6 h incubation TNF-a was 
added to the cells. Incubation was continued for 72 h, followed by 
a cytotoxicity assay. 
2.4. TNF-a cytotoxicity assay 
Cell viability was measured by staining with crystal violet as pre-
viously described [5,11,13]. After washing with phosphate buffered 
saline, cells were fixed with methanol for 5 min and then stained for 
10 min with a 0.1% crystal violet solution. Following three washes 
with tap water, the dye was eluted with 0.1 mol/1 trisodium citrate in 
50% ethanol for 1 h. Optical density at 630 nm was measured using a 
microtiter plate reader. 
3. Results 
In endothelial cells, treatment with T N F - a (50 ng/ml) 
markedly reduced the number of viable cells (Fig. 1). A 6 h 
preincubation with Sper/NO (0.03-1 uM) protected endothe-
lial cells from TNF-a-media ted cytotoxicity in a concentra-
tion-dependent manner and increased viability by up to 63% 
of control (Fig. 1). The specific N O scavenger PTIO (30 ^ M ) 
completely abolished cytoprotection by Sper/NO (Fig. 2). A 
cytoprotective effect comparable to Sper/NO was observed 
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Fig. 1. Effect of Sper/NO on TNF-a-mediated cytotoxicity in endothelial cells. Incubations were carried out as described in Section 2. 
*: P<0.05, Sper/NO vs. control (CON), two-tailed t-test. All data shown are mean ± SEM of n = 6 observations. 
when preincubating the cells with 8-bromo cyclic GMP (1-10 
|J,M, Fig. 3). Moreover, no protection by Sper/NO occurred in 
the presence of ODQ (0.1 |0.M), a selective inhibitor of the 
NO-sensitive soluble guanylyl cyclase (Fig. 2). Sper/NO, 
PTIO, ODQ, and 8-bromo cyclic GMP alone had no signifi-
cant effect on cell viability under these conditions (not 
shown). 
4. Discussion 
The present study demonstrates protection from TNF-a-
mediated toxicity in endothelial cells by the NO donor Sper/ 
NO. The observed protection can be attributed to the free NO 
radical since Sper/NO-induced cytoprotection was completely 
abolished in the presence of the NO radical scavenger PTIO 
[14]. Moreover and as an additional control, NO-free sper-
mine tetrahydrochloride did not reduce TNF-a-dependent en-
dothelial toxicity (not shown). Antioxidant and cytoprotective 
effects of NO have been reported before, particularly with 
respect to exogenous sources of oxygen radicals such as hy-
drogen peroxide [4,5]. This is one of the first studies to show 
that NO reduces endothelial injury by TNF-a and may thus 
interfere with initiating events of inflammation and atheroscle-
rosis. 
We and others have previously shown that generation of 
oxygen radicals plays a crucial role in endothelial cell killing 
by TNF-a [10-12]. It is therefore conceivable that the known 
antioxidant effect of NO contributes to the increased resist-
ance of endothelial cells against TNF-a-mediated toxicity. 
However, a direct quenching of Superoxide radicals as under-
Fig. 2. Effect of PTIO and ODQ on Sper/NO-induced cytoprotection from TNF-a-mediated toxicity in endothelial cells. Incubations were car-
ried out as described in Section 2. *: P<0.05, treatment vs. control (CON), two-tailed t-test. All data shown are meant SEM of n = 6 observa-
tions. 
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Fig. 3. Effect of 8-bromo cyclic GMP (8-Br-cGMP) on TNF-a-mediated cytotoxicity in endothelial cells. Incubations were carried out as de-
scribed in Section 2. *: P<0.05, 8-Br-cGMP vs. control (CON), two-tailed t-test. All data shown are mean ± SEM of « = 6 observations. 
lying mechanism seems unlikely, since the endothelial protec-
tion was fully expressed only after 6 h of pretreatment with 
Sper/NO prior to the addition of TNF-a. Our data rather 
suggest NO to trigger long-term signal transduction processes 
which may lead to the up-regulation of protective proteins 
such as heme oxygenase, ferritin, or HSP70 [6,7,15]. This as-
sumption is strongly supported by our finding that ODQ, a 
selective inhibitor of soluble guanylyl cyclase [16], abolished 
the endothelial protection by Sper/NO suggesting the second 
messenger cyclic GMP as responsible mediator. A signaling 
function for cyclic GMP can also be derived from our obser-
vation that the membrane penetrating analog 8-bromo cyclic 
GMP mimicked the cytoprotective action of Sper/NO. Thus, 
cyclic GMP-dependent pathways could represent alternative 
routes by which NO in addition to direct nitrosylation of 
protein thiols [15,17] modulates cellular adaptation to stress 
caused by TNF-a and other cytotoxic agents. 
Together, our results show that NO reduces endothelial 
injury by TNF-rx, possibly via a cyclic GMP-dependent mech-
anism. These observations underline the importance of NO in 
maintaining vascular wall integrity and point to the antiin-
flammatory/antiatherogenic potential of NO. 
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